These factors collectively drive the market's growth and the pursuit of more effective and personalized pancreatic cancer treatments.” Oncolytics Biotech® Inc.(NASDAQ: ONCY) (TSX: ONC) to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium - Pelareorep combination therapy shows continued meaningful improvement over checkpoint inhibitors alone in anal cancer patientsPelareorep-based therapy demonstrates strong safety profile with new chemotherapy regimen in pancreatic cancer patients Oncolytics Biotech® Inc., ($ONCY $ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today provided details from the abstracts featuring pelareorep that are being presented at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco January 23-25, 2025.Thomas Heineman, M.D., Ph.D., Chief Medical Officer for Oncolytics Biotech, commented, "The posters that will be presented at the symposium later this week continue to show pelareorep’s compelling potential in gastrointestinal cancers.
"I’ve been especially impressed with the ability of pelareorep-based therapies to work across multiple challenging cancer indications and with multiple standards of care, including chemotherapy and checkpoint inhibitors, so I look forward to additional data readouts that can help improve the treatment paradigm.” CONTINUED… Read these full press releases and more news for ONCY at: Other recent oncology developments in the biotech industry of note include: AstraZeneca PLC (NASDAQ: AZN) DATROWAY® (datopotamab deruxtecan-dlnk) has recently been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
We look forward to continuing our work with Bristol Myers Squibb and progressing the AB-4000 series toward clinical development to potentially benefit patients with solid tumors.” About FN Media Group: At FN Media Group, via our top-rated online news portal at we are one of the very few select firms providing top tier one syndicated news distribution, targeted ticker tag press releases and stock market news coverage for today’s emerging companies.#pressreleases #tickertagpressreleases Follow us on Facebook to receive emerging news updates: Follow us on Twitter for real time Breaking News: Follow us on Linkedin: DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.
The story "Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus" has 1857 words across 61 sentences, which will take approximately 8 - 16 minutes for the average person to read.
Which news outlet covered this story?
The story "Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus" was covered 1 days ago by GlobeNewswire, a news publisher based in China.
How trustworthy is 'GlobeNewswire' news outlet?
GlobeNewswire is a fully independent (privately-owned) news outlet established in 1998 that covers mostly technology news.
The outlet is headquartered in China and publishes an average of 34 news stories per day.
It's most recent story was published 8 hours ago.
What do people currently think of this news story?
The sentiment for this story is currently Negative, indicating that people regard this as "bad news".
How do I report this news for inaccuracy?
You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
